Health care remains one of the most durable and structurally supported segments of the U.S. equity market, driven by demographic aging, therapeutic innovation, and relatively defensive demand. Investors seeking exposure often confront a choice between a narrow, high-conviction pharmaceutical vehicle and a broad sector fund. IHE and XLV embody that trade-off. They are not direct competitors in strategy but represent alternative routes to similar investor goals: capturing health care growth while managing risk. This ETF comparison examines how their structural differences, cost profiles, and relative positioning shape outcomes across recent market cycles. I also checked this using Tickeron’s AI Screener to see how the two line up on key metrics.
IHE is a passively managed exchange-traded fund that seeks to track the Dow Jones U.S. Select Pharmaceuticals Index, a capitalization-weighted benchmark of U.S. pharmaceutical companies. The fund holds roughly 57 positions, a relatively concentrated lineup for a sector product. Its top holdings are dominated by LLY (Eli Lilly) and JNJ (Johnson & Johnson), which together account for close to 50% of assets, followed by smaller weights in VTRS (Viatris), RPRX (Royalty Pharma), ZTS (Zoetis), PFE (Pfizer), MRK (Merck), BMY (Bristol-Myers Squibb), JAZZ (Jazz Pharmaceuticals), and ELAN (Elanco).
Because the fund focuses exclusively on pharmaceuticals, its exposure is essentially 100% concentrated in one industry. This is a high-conviction, thematic approach: investors get pure drug-manufacturer exposure but absorb outsized single-stock risk and sensitivity to drug-pricing headlines, patent cliffs, and clinical-trial outcomes. The expense ratio is 0.37%, higher than broad sector peers.
XLV is a passively managed ETF that seeks to track the Health Care Select Sector Index, which draws health care companies from the S&P 500. It holds roughly 60 to 64 large-cap names spanning pharmaceuticals, biotechnology, health care equipment and supplies, health care providers and services, and life sciences tools. Top holdings include LLY (Eli Lilly), JNJ (Johnson & Johnson), ABBV (AbbVie), MRK (Merck), UNH (UnitedHealth Group), TMO (Thermo Fisher Scientific), AMGN (Amgen), GILD (Gilead Sciences), ABT (Abbott Laboratories), and PFE (Pfizer). From what I see in the data, the broader mix helps moderate swings.
This diversified sector allocation is the fund's defining feature. By spreading exposure across manufacturers, equipment makers, insurers, and diagnostics firms, XLV dilutes any single company's influence and smooths the impact of one sub-industry's downturn. Its expense ratio of 0.08% is among the lowest in the category, and its substantial scale and trading volume support tight spreads and strong liquidity for institutional and retail investors alike.
The broader health care environment has been shaped by several overlapping forces. GLP-1 weight-loss drugs have powered significant growth for large pharmaceutical leaders, lifting the biggest holdings in both funds. At the same time, policy debate over drug pricing, Medicare reimbursement, and pharmacy benefit managers has created recurring headline risk, particularly for pure-play pharmaceutical and insurance exposures. Elevated-for-longer interest-rate expectations have weighed on higher-multiple biotechnology and growth names, while defensive cash flows have attracted capital seeking stability in uncertain macro conditions. Capital flows in recent market cycles have favored diversified health care vehicles over narrow industry funds, reflecting a preference for balanced risk in a volatile policy landscape.
In recent weeks and months, both funds have benefited from strength in their shared top holdings, especially LLY and JNJ. However, relative performance has diverged along structural lines. IHE has shown greater sensitivity to pharmaceutical-specific catalysts, producing more pronounced swings when drug-pricing rhetoric or obesity-drug news dominates headlines. Its concentration in two mega-cap names means its fund performance often tracks the earnings cycles of a narrow set of companies.
XLV, by contrast, has delivered steadier relative positioning, as strength in pharmaceuticals is partially offset by more muted performance in managed care or equipment names, and vice versa. Its lower beta and broader industry mix have made it less volatile across recent market cycles, a key consideration for investors prioritizing consistency over maximum upside capture.
I often turn to Tickeron’s AI Screener when comparing sector ETFs like these. It lets me quickly filter by expense ratio, holdings concentration, and sub-industry exposure to see how the risk profiles stack up. The tool has helped refine my own workflow for spotting balanced options without manual number crunching.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
The 10-day RSI Oscillator for IHE moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 instances where the indicator moved out of the overbought zone. In 31 of the 36 cases the stock moved lower in the days that followed. This puts the odds of a move down at 86%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IHE as a result. In 66 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for IHE turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
IHE broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
IHE moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +1.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where IHE advanced for three days, in 286 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 246 of 288 cases where IHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows